The FinancialContent Network     SocialPicks Community   |   MarketMinute Monitor   |   MarketMinute Market Updates   |   MarketMinute Stock News
SocialPicks
   Sign Up   |   Log In   |   What is SocialPicks?     
8 pts

Opinion on  BioElectronics Corp. (BIEL)
Drug free relief of edema and discomfort

Apr 07, 2008 01:45 PM GMT
Waterfall
Return Risk
-17.62% HIGH
Associate

BioElectronics Launches '1 Day Breast Augmentation Recovery Kit'
Thursday March 13, 7:15 am ET 
Meets the Growing Demand for Quicker Surgical Recoveries


FREDERICK, Md., March 13 /PRNewswire-FirstCall/ -- BioElectronics Corporation (BIEL) announces the product launch of its Breast Recovery Kit, for the relief of edema and post operative discomfort.
Developed by Dr. Barry Eppley, MD, DMD, the 1 Day Breast Recovery Kit allows breast surgery patients to return to their active lives the day after surgery. Using the patented technology, ActiPatch relieves edema and discomfort without drugs, ice, or topical ointments. Priced below $50.00 it is an excellent alternative to pain pumps, which pose a risk of infection, or oral analgesics and anti-inflammatory medications -- which many patients prefer not to take or cannot tolerate.

Dr. Barry L. Eppley is an extensively trained and unique plastic surgeon. Dr. Eppley received a Doctor of Medicine degree from Washington University in St. Louis as well as a Doctor of Dental Medicine degree from the University of Pennsylvania in Philadelphia. Dr. Eppley completed training in Oral and Maxillofacial Surgery at Barnes Hospital and St. John's Mercy Medical Center Hospital while in St. Louis. He furthered his training in General Surgery, Craniofacial and Cleft Surgery as well as full training in Plastic and Reconstructive Surgery at Indiana University. As a result of this education, Dr. Eppley is both a licensed physician and dentist and board certified in the specialties of Plastic and Reconstructive Surgery as well as Oral and Maxillofacial Surgery. This background brings a diverse experience and perspective to the requirements needed for facial plastic, craniofacial and maxillofacial, and cosmetic body contouring surgeries. For more visit: http://www.dreppley.com.

"We are thrilled and quite fortunate to have such a talented surgeon and educator as Dr. Eppley assisting in our product development. We look forward to his insight and help in our mission to change the way people heal," said BioElectronics' President Andrew Whelan.

ActiPatch(TM) is a drug-free, anti-inflammatory patch with an embedded battery operated microchip that delivers weeks of continuous pulsed therapy for less than a dollar a day. The unique ActiPatch(TM) delivery system, using patented technology, provides a cost-effective, patient friendly method to reduce soft tissue pain and swelling.

ActiPatch has regulatory clearance by the FDA for the treatment of edema following blepharoplasty.

For more information visit http://www.bioelectronicscorp.com or call 866-757-2284.

 


--------------------------------------------------------------------------------
Source: BioElectronics Corporation


BIEL:  This call was made on 04/07/08 @ $0.034
Rating:   Positive   $0.034 (04/07/08)
Closed:   04/16/2008 @ $0.03 (-11.76% in 9 days)


+ Referring to this analysis:


Add Comment

Be the first to comment on this story and earn 2 points.

Your Comment

Who voted on this idea?
bfenster91 N/A 05/21/2008
Keith 32% 04/07/2008


Ratings referring to this analysis Agree     Disagree



ROCK-STAR INVESTORS
Rank Name Sharpe Ratio Avg Return Followers
1 21.10 +34.44% 381
2 18.14 +71.24% 211
3 17.66 +25.60% 55
4 13.47 +14.32% 62
5 12.13 +74.22% 40


POPULAR STOCKS
Symbol Company Name Sentiment

TODAY'S HEADLINES

TODAY'S TOP PICKS

 
BioElectronics Corp. (BIEL)
   SocialPicks Sentiment:   

   This Quarter's Sentiment:
All:
66.0%
Top:
0.0%




Latest Picks by Furry Sound
Symbol SP Sentiment Rating Return Since
CBAY N/A Positive n/a 08/28/08
WAVL N/A Positive n/a 08/28/08
OLNK N/A Positive -76.67% 01/28/08
SGGC Positive n/a 12/24/07
BNPD N/A Positive n/a 11/28/07

View All >
   




IN THE PRESS
Press_forbes Press_washingtonpost Press_wsj Press_npr Press_techcrunch